From the publishers of JADPRO
CAR T-Cell Therapy
Resource Center
Menu
Resources
Videos
Videos
Fast Facts
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Interview With Patricia Mangan, MSN, CRNP: CAR T-Cell Therapy: Adverse Events
Last Updated: Thursday, October 21, 2021
Advertisement
News & Literature Highlights
Frontiers in Immunotherapy
Smart control of CAR-T cells: Emerging strategies for safer and more effective cancer immunotherapy
Molecular Therapy
CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors
Nature Medicine
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: A phase 1 study
Frontiers in Oncology
Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: A systematic review and meta-analysis
Journal of Translational Medicine
Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer
Trends in Cancer
In vivo CAR T cell engineering: Design principles and open questions
Blood Cancer Discovery
Multiomic and longitudinal dissection of immune dynamics associated with parkinsonism after ciltacabtagene autoleucel therapy
Blood Advances
Non-ICANS neurologic toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients
Molecular Immunology
Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions
Cancer
Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis
Advertisement
Case Studies
Identifying and Managing CAR T-Associated Hemophagocytic Lymphohistiocytosis Following Dual-Targeted CAR T-Cell Therapy
Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations
Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma
Fast Facts
Fast Facts #12: BCMA Targets
Advertisement
Quizzes
Test your knowledge of CAR T-associated HLH following dual-targeted CAR T-cell therapy
Test your knowledge of prophylactic strategies in selected high-risk or outpatient CAR-T populations
How much have you learned this year?